Characterization of KRAS rearrangements in metastatic prostate cancer. - Wikidata - wikimedia - TriplyDB

Characterization of KRAS rearrangements in metastatic prostate cancer.

Characterization of KRAS rearrangements in metastatic prostate cancer.

http://www.wikidata.org/entity/Q35581673

about

The mutational landscape of prostate cancer Integrative clinical genomics of advanced prostate cancer.Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients Manumycin induces apoptosis in prostate cancer cells The Molecular Taxonomy of Primary Prostate Cancer.Genomic rearrangements in prostate cancer.The biology of castration-resistant prostate cancer Coordinated regulation of polycomb group complexes through microRNAs in cancer.Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.BRAF Mutations in Canine Cancers.Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination.OLA1 protects cells in heat shock by stabilizing HSP70.Precision medicine for advanced prostate cancer.ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.Advancing precision medicine for prostate cancer through genomics.Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis.Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.Recurrent gene fusions in prostate cancer: their clinical implications and uses.A basal cell defect promotes budding of prostatic intraepithelial neoplasia.Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.The role of wild type RAS isoforms in cancer.ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma.The genomic landscape of prostate cancer.Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer.An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer

P2860

Q26851631-4F90B5A7-FB86-46CA-9419-9D803F58C8E6 Q27853170-36D91F37-1F9B-4A0F-A3E6-88486E497409 Q30414829-AFFD0024-E470-461D-9B59-3A8C93CC8774 Q33559632-CE2CD07C-A273-49A9-873A-796754434B71 Q33689772-927EB415-45B8-43AC-BC60-3F2F982BE64C Q34674332-DA1067E4-E01C-4920-ADC1-263EECD6CFE2 Q34722101-7EEF18D7-A123-46E3-8150-6B57C6D25AD7 Q35039889-2C6110F3-1DA4-4DC1-ADA6-4716C1955CE9 Q35167450-719D6CE2-BFC1-42AD-A81F-1BAF43378C37 Q35567256-4BD73257-5E9A-4BC8-8E6C-CA959637AEB6 Q35573029-DD5407F5-2B68-4F56-B035-A5A7C269626C Q35656395-C7A9543E-DC2C-4608-8A63-A297E807DDBD Q35871737-F8B5EA1A-A896-434F-A127-2EBD3E31AD36 Q36636063-70208254-F16C-480D-A5BB-4C02D912CCF0 Q37073628-A2AD2FA7-97DB-4F6C-A78A-1F799EF0DBC4 Q37114034-DD28D9A2-DA20-4266-B1F6-E2D57DB91AD3 Q37173209-253C55AB-BF99-4962-8D49-07D8B49CBA1F Q37255151-F222C6D3-9D4F-4367-9358-4C8EB783A0B6 Q37338907-13E61E56-8E64-4033-8A77-6FF1B2C23693 Q37583441-053951E9-8496-4A0E-8EA7-F7E9FE13437C Q37663786-912091B7-FD1F-4DE4-B14A-2F65F04256DC Q38056848-2997FC39-BB31-4CDC-8737-7115E163D08C Q38102618-A5A7E051-8BAC-4565-A876-D80A02A2E8D6 Q38747491-7CB9CD49-9BCE-4D33-92AD-202739E0AEF1 Q38768199-D336FFBD-4635-4410-9C23-C46F24E466AF Q38898397-CF7375B7-34F7-4382-AD1A-E42A1EFA3942 Q38949808-EAA8ADCB-2904-4C34-BD78-DAA1B8BD6D2E Q38970398-F44FB35F-6B37-40C0-B4F3-6EF29428F364 Q39044222-D46EE0F9-CF7C-4F07-B915-653C97C38C65 Q39113275-C154394E-EA48-4E3A-B4AE-3CC93EA9D897 Q39206549-81FE6977-2CDF-4385-8F0B-B661F6417DEA Q40394844-6AA3EB0E-0675-469D-9AA1-7E81AD265FDD Q42174920-7E7A61C9-961C-46A4-AA88-614AE3474FC1 Q42258471-EF3C5BDC-6A3C-4219-8CAF-DFB5447964B8 Q42363305-246E196C-440E-400C-9E1A-86EA96425E62 Q42500743-37E4D5EB-2F5B-4249-803D-BD4578184366 Q47379977-889F0338-EA5F-4332-A457-7FE81B6878FF Q48239804-1C16E95D-876A-4C6A-A9E4-2FF41A74B109 Q48240280-33BA29A7-7BB7-4723-A935-4ABA0F5BFF61 Q58561130-72953A55-4A89-46A0-83A8-525D93386EBE

P2860

Characterization of KRAS rearrangements in metastatic prostate cancer.

http://www.wikidata.org/entity/Q35581673

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Characterization of KRAS rearrangements in metastatic prostate cancer.

@ast

Characterization of KRAS rearrangements in metastatic prostate cancer.

@en

type

label

Characterization of KRAS rearrangements in metastatic prostate cancer.

@ast

Characterization of KRAS rearrangements in metastatic prostate cancer.

@en

prefLabel

Characterization of KRAS rearrangements in metastatic prostate cancer.

@ast

Characterization of KRAS rearrangements in metastatic prostate cancer.

@en

P1433

Q35581673-88809633-8872-4641-BD2F-98B01CB16608

P1476

Q35581673-28ABB873-E839-43D5-B9CD-4145B3F69A79

P2093

Q35581673-02C6C8C7-C286-4D46-A18D-5AD4D117644B

Q35581673-12E4AA8D-1948-4F50-A76C-78E06C31AA0C

Q35581673-18924473-F13A-4BC6-B123-F09F507C7B99

Q35581673-1FD05978-5B20-4C1E-B7D6-2183C760BCE9

Q35581673-4AC45E02-264E-49BE-B866-7F98E4735427

Q35581673-54BBDB5A-17C9-4238-A0FD-F393F2CD968E

Q35581673-5787AC54-EA85-4356-A039-2C67CCF83F33

Q35581673-6184486F-C10B-43AE-B148-1F1392B293DA

Q35581673-671A1919-E06A-4D75-9963-9CBE23F311E8

Q35581673-7C115A04-8FE3-4BAD-9262-2CBCBBD7E977

P2860

Q35581673-034E26DD-FC17-4C35-A3C6-36F145D95A66

Q35581673-1E45CFE0-91ED-4D41-8222-2D38850A50E1

Q35581673-2F7FA3B2-FB71-457D-8126-5DE99387519F

Q35581673-3693CAE5-51F6-443B-92C7-4C4B63A1B453

Q35581673-4D124CE1-A1B7-4325-9357-8A58A09FF9AE

Q35581673-4FF83F96-5B96-435F-8DFB-136C9CB16FC4

Q35581673-57639529-01D6-41E1-A904-42F7A90B79E2

Q35581673-758B256E-DDAF-4563-A30C-29E4A2CABB36

Q35581673-7731CD12-735C-4849-87F0-9618618BCC45

Q35581673-785E64AE-C64B-4006-A8F1-1E30350FD32B

P304

Q35581673-D15C9904-92F2-4820-9B39-BCFBEBD45A73

P31

Q35581673-5E54A46C-3850-4B10-B4A5-C3B0B98512CF

P356

Q35581673-6D50616F-1B41-4920-9EB4-525AB1E50DAA

P433

Q35581673-4DD7DF3A-AEE3-42FE-AA4E-49F4361A1E6E

P478

Q35581673-BCD521A5-FF23-41E8-AD0B-70A225052C2A

P50

Q35581673-22EE8C01-DE17-4F26-AB84-0214EFF401C5

Q35581673-2ADFB94E-9DEF-4613-B164-6C7A3456702C

Q35581673-2E2E6F73-E9D3-4302-9FFE-41A1C90E6F48

Q35581673-41CA36C8-00B7-4E23-AF09-E6763B827D14

Q35581673-67B424EA-8DB6-45B9-B433-1E6426921737

Q35581673-B1E0E496-2CF5-4D05-913F-B7BE66F32B26

Q35581673-BBB68241-8FAA-430E-B3FC-BBC32DB2755D

Q35581673-F17D8BE6-38F1-438F-8274-C17620A5975D

Q35581673-F83778A7-604D-4116-8FFF-98869FD05A58

P577

Q35581673-CEB06A4D-51C9-4CBD-AA0F-A766988CEEFA

P5875

Q35581673-0361F141-447C-4471-A780-BE01B60C5862

P698

Q35581673-AB94EAC0-E255-4829-9576-7D853AF1AC96

P932

Q35581673-05A29D78-6233-43AF-99BB-D746D2D467D1

P356

2159-8274.CD-10-0022

P1433

Cancer Discovery

P1476

Characterization of KRAS rearrangements in metastatic prostate cancer.

@en

P2093

Anastasia K Yocum

http://www.w3.org/2001/XMLSchema#string

Anuradha Gopalan

http://www.w3.org/2001/XMLSchema#string

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Atsuo T Sasaki

http://www.w3.org/2001/XMLSchema#string

Bo Han

http://www.w3.org/2001/XMLSchema#string

Daniel F Fries

http://www.w3.org/2001/XMLSchema#string

Daniel Robinson

http://www.w3.org/2001/XMLSchema#string

Dorothee Pflueger

http://www.w3.org/2001/XMLSchema#string

Emily Rose Kahoud

http://www.w3.org/2001/XMLSchema#string

Rui Wang

http://www.w3.org/2001/XMLSchema#string

P2860

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Fine-mapping, genomic organization, and transcript analysis of the human ubiquitin-conjugating enzyme gene UBE2L3

In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma

Ras oncogenes: split personalities

Circular binary segmentation for the analysis of array-based DNA copy number data

Hyperactive Ras in developmental disorders and cancer

An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses

P304

35-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8274.CD-10-0022

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Lewis C. Cantley

John R. Prensner

Nallasivam Palanisamy

Sooryanarayana Varambally

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51852778

http://www.w3.org/2001/XMLSchema#string

P698

22140652

http://www.w3.org/2001/XMLSchema#string

P932

3227139

http://www.w3.org/2001/XMLSchema#string